User:Ely.yatun/Flurbiprofen

Pharmacogenomics
When it comes to genetic testing in the case of Flurbiprofen the gene of interest is CYP2C9. CYP2C9 is the main contributor to the metabolization of Flurbiprofen so if the gene is inactive the patient will have a high concentration of medication in their blood leading to a higher chance of experiencing side effect. The FDA labels this interaction as actionable meaning that it is suggested to do a genetic test before using Flurbiprofen. When planning on using this medication health care providers should verify the activity score of CYP2C9 (if available) and adjust the treatment based on the following criteria:

Activity score of 2 (normal metabolizer)

 * Use regular dose.
 * Use regular duration of treatment.
 * Low chance of adverse effects.

Activity score of 1.5 (intermediate metabolizer)

 * Use regular dose.
 * Use regular duration of treatment.
 * no significant increase in side effects.

Activity score of 1 (intermediate metabolizer)

 * Avoid the use of Flurbiprofen.
 * Increased chance of significant side effects.

Activity score of 0 - 0.5 (poor metabolizer)

 * Avoid the use of Flurbiprofen.
 * Increased chance of significant side effects.